南京医药
(600713)
| 流通市值：49.20亿 | | | 总市值：61.58亿 |
| 流通股本：10.47亿 | | | 总股本：13.10亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 53,589,664,728.2 | 40,546,782,609.42 | 27,343,124,491.26 | 14,081,790,518.45 |
| 营业收入 | 53,589,664,728.2 | 40,546,782,609.42 | 27,343,124,491.26 | 14,081,790,518.45 |
| 二、营业总成本 | 52,645,439,177.52 | 39,807,137,866.72 | 26,842,261,694.47 | 13,822,101,709.4 |
| 营业成本 | 50,276,361,667.87 | 38,083,380,912.56 | 25,706,228,543.81 | 13,268,001,418.96 |
| 税金及附加 | 107,592,787.25 | 73,711,904.25 | 44,549,073.18 | 20,646,837.02 |
| 销售费用 | 1,173,100,689.57 | 858,872,969.53 | 567,138,498.29 | 287,921,466.04 |
| 管理费用 | 517,443,394.34 | 361,685,815.49 | 238,652,009.07 | 111,037,513.88 |
| 研发费用 | 36,189,149.34 | 28,507,614.74 | 17,900,905.5 | 8,367,640.19 |
| 财务费用 | 534,751,489.15 | 400,978,650.15 | 267,792,664.62 | 126,126,833.31 |
| 其中:利息费用 | 378,493,807.68 | 288,552,681.16 | 188,703,835.39 | 92,185,966.37 |
| 其中:利息收入 | 10,135,446.88 | 8,210,697.8 | 4,932,721.73 | 3,851,312.38 |
| 加:投资收益 | 8,581,039.56 | 8,707,652.08 | 3,960,564.27 | -748,430.95 |
| 资产处置收益 | 2,197,111.2 | -52,303.79 | 181,657.7 | -58,973.24 |
| 资产减值损失(新) | -6,248,448.65 | -3,943,526.21 | -3,377,880.76 | -195,393.23 |
| 信用减值损失(新) | 19,292,413.03 | -20,550,475.79 | 9,696,899.37 | -12,635,805.76 |
| 其他收益 | 39,395,059.31 | 30,887,227.04 | 24,047,706.67 | 6,084,270.41 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,007,442,725.13 | 754,693,316.03 | 535,371,744.04 | 252,134,476.28 |
| 加:营业外收入 | 2,566,390.75 | 2,374,060.81 | 1,596,475.44 | 301,591.5 |
| 减:营业外支出 | 31,941,001.95 | 24,887,096.96 | 15,447,038.02 | 7,393,059.03 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 978,068,113.93 | 732,180,279.88 | 521,521,181.46 | 245,043,008.75 |
| 减:所得税费用 | 265,259,209.01 | 199,215,801.76 | 145,730,049.15 | 61,437,900.78 |
| 六、净利润 | 712,808,904.92 | 532,964,478.12 | 375,791,132.31 | 183,605,107.97 |
| 持续经营净利润 | 712,808,904.92 | 532,964,478.12 | 375,791,132.31 | 183,605,107.97 |
| 归属于母公司股东的净利润 | 577,825,648.39 | 440,295,384.86 | 308,641,881.41 | 149,157,852.44 |
| 少数股东损益 | 134,983,256.53 | 92,669,093.26 | 67,149,250.9 | 34,447,255.53 |
| (一)基本每股收益 | 0.45 | 0.34 | 0.24 | 0.11 |
| (二)稀释每股收益 | 0.45 | 0.34 | 0.24 | 0.11 |
| 八、其他综合收益 | 7,536,148.64 | 5,029,004.34 | 8,869,054.19 | 17,488,458.51 |
| 归属于母公司股东的其他综合收益 | 7,748,553.76 | 5,367,931.83 | 8,908,416.94 | 17,313,057.07 |
| 九、综合收益总额 | 720,345,053.56 | 537,993,482.46 | 384,660,186.5 | 201,093,566.48 |
| 归属于母公司股东的综合收益总额 | 585,574,202.15 | 445,663,316.69 | 317,550,298.35 | 166,470,909.51 |
| 归属于少数股东的综合收益总额 | 134,770,851.41 | 92,330,165.77 | 67,109,888.15 | 34,622,656.97 |
| 公告日期 | 2024-04-08 | 2023-10-31 | 2023-08-31 | 2023-04-29 |
| 审计意见(境内) | 标准无保留意见 | | | |